Noncovalent interactions of drugs with immune receptors may mediate drug-induced hypersensitivity reactions

AAPS Journal

Volumn 8, Issue 1, 2006, Pages

  Gerber, Basil O ^a   Pichler, Werner J ^a  

^a Clinic for Rheumatology and Clinical Immunology/Allergology   (Switzerland)

Author keywords

Cross reactivity; Drug hypersensitivity; Hapten; p i concept; Prohapten; T cells; T cell receptor

Indexed keywords

ALLOPURINOL; BENZENE DERIVATIVE; CARBAMAZEPINE; CONTRAST MEDIUM; DIAMINE DERIVATIVE; HAPTEN; HLA ANTIGEN; HLA B57 ANTIGEN; LAMOTRIGINE; LIDOCAINE; MAJOR HISTOCOMPATIBILITY ANTIGEN; MEPIVACAINE; NITROSO DERIVATIVE; SULFAMETHOXAZOLE; T LYMPHOCYTE RECEPTOR;

ANTIGEN BINDING; ANTIGEN PRESENTATION; ARTICLE; COMPLEX FORMATION; COVALENT BOND; CROSS REACTION; DRUG EXPOSURE; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG RECEPTOR BINDING; HUMAN; HYPERSENSITIVITY REACTION; IMMUNE RESPONSE; IMMUNITY; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR WEIGHT; NONHUMAN; PROTEIN MODIFICATION; STEVENS JOHNSON SYNDROME; T LYMPHOCYTE ACTIVATION; TOXIC EPIDERMAL NECROLYSIS;

ANIMALS; DRUG HYPERSENSITIVITY; HUMANS; PHARMACEUTICAL PREPARATIONS; RECEPTORS, IMMUNOLOGIC;

EID: 33645472352     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/aapsj080119     Document Type: Article

References (47)

1. Park BK, Pirmohamed M, Kitteringham NR. Role of drug disposition in drug hypersensitivity: a chemical, molecular, and clinical perspective. Chem Res Toxicol. 1998; 11:969-987.
2. Naisbitt DJ, Gordon SF, Pirmohamed M, Park BK. Immunological principles of adverse drug reactions: the initiation and propagation of immune responses elicited by drug treatment. Drug Saf. 2000;23:483-507.
3. Pichler WJ. Delayed drug hypersensitivity reactions. Ann Intern Med. 2003;139:683-693.
4. Manfredi M, Severino M, Testi S, et al. Detection of specific IgE to quinolones. J Allergy Clin Immunol. 2004;113:155-160.
5. Pichler WJ, Schnyder B, Zanni MP, Hari Y, von Greyerz S. Role of T cells in drug allergies. Allergy. 1998;53:225-232.
6. Yawalkar N, Egli F, Hari Y, Nievergelt H, Braathen LR, Pichler WJ. Infiltration of cytotoxic T cells in drug-induced cutaneous eruptions. Clin Exp Allergy. 2000;30:847-855.
7. Naisbitt DJ, Farrell J, Wong G, et al. Characterization of drug-specific T cells in lamotrigine hypersensitivity. J Allergy Clin Immunol. 2003;111:1393-1403.
8. Naisbitt DJ, Britschgi M, Wong G, et al. Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype, and cytokine profile of drug-specific T cell clones. Mol Pharmacol. 2003;63:732-741.
9. Pichler WJ. Drug-induced autoimmunity. Curr Opin Allergy Clin Immunol.2003;3:249-253.
10. Padovan E, Bauer T, Tongio MM, Kalbacher H, Weltzien HU. Penicilloyl peptides are recognized as T cell antigenic determinants in penicillin allergy. Eur J Immunol. 1997;27:1303-1307.
11. Cavani A, Hackett CJ, Wilson KJ, Rothbard JB, Katz SI. Characterization of epitopes recognized by hapten-specific CD4+ T cells. J Immunol.1995;154:1232-1238.
12. Cavani A, Mei D, Guerra E, et al. Patients with allergic contact dermatitis to nickel and nonallergic individuals display different nickel-specific T cell responses: evidence for the presence of effector CD8+ and regulatory CD4+ T cells. J Invest Dermatol. 1998;111:621-628.
13. Gamerdinger K, Moulon C, Karp DR, et al. A new type of metal recognition by human T cells: contact residues for peptide-independent bridging of T cell receptor and major histocompatibility complex by nickel. J Exp Med. 2003; 197:1345-1353.
14. Lu L, Vollmer J, Moulon C, Weltzien HU, Marrack P, Kappler J. Components of the ligand for a Ni++ reactive human T cell clone. J Exp Med. 2003;197:567-574.
15. Griem P, Wulferink M, Sachs B, Gonzalez JB, Gleichmann E. Allergic and autoimmune reactions to xenobiotics: how do they arise? Immunol Today. 1998; 19:133-141.
16. Knowles SR, Uetrecht J, Shear NH. Idiosyncratic drug reactions: the reactive metabolite syndromes. Lancet. 2000;356:1587-1591.
17. Schnyder B, Mauri-Hellweg D, Zanni M, Bettens F, Pichler WJ. Direct, MHC-dependent presentation of the drug sulfamethoxazole to human alphabeta T cell clones. J Clin Invest. 1997; 100: 136-141.
18. Zanni MP, von Greyerz S, Schnyder B, et al. HLA-restricted, processing-and metabolism-independent pathway of drug recognition by human alpha beta T lymphocytes. J Clin Invest. 1998;102:1591-1598.
19. Zanni MP, von Greyerz S, Hari Y, Schnyder B, Pichler WJ. Recognition of local anesthetics by alphabeta+ T cells. J Invest Dermatol. 1999;112:197-204.
20. Zanni MP, Mauri-Hellweg D, Brander C, et al. Characterization of lidocaine-specific T cells. J Immunol. 1997; 158:1139-1148.
21. Sieben S, Kawakubo Y, Al Masaoudi T, Merk HF, Blomeke B. Delayed-type hypersensitivity reaction to paraphenylenediamine is mediated by 2 different pathways of antigen recognition by specific alphabeta human T-cell clones. J Allergy Clin Immunol. 2002;109:1005-1011.
22. Depta JP, Altznauer F, Gamerdinger K, Burkhart C, Weltzien HU, Pichler WJ. Drug interaction with T-cell receptors: T-cell receptor density determines degree of cross-reactivity J Allergy Clin Immunol. 2004;113:519-527.
23. Cribb AE, Spielberg SP. Sulfamethoxazole is metabolized to the hydroxylamine in humans. Clin Pharmacol Ther. 1992;51:522-526.
24. Naisbitt DJ, Vilar FJ, Stalford AC, Wilkins EG, Pirmohamed. M, Park BK. Plasma cysteine deficiency and decreased reduction of nitrososulfamethoxazole with HIV infection. AIDS Res Hum Retroviruses. 2000;16:1929-1938.
25. Schnyder B, Burkhart C, Schnyder-Frutig K, et al. Recognition of sulfamethoxazole and its reactive metabolites by drug-specific CD4+ T cells from allergic individuals. J Immunol. 2000; 164:6647-6654.
26. Burkhart C, von Greyerz S, Depta JP, et al. Influence of reduced glutathione on the proliferative response of sulfamethoxazole-specific and sulfamethoxazole-metabolite-specific human CD4+ T cells. Br J Pharmacol. 2001;132:623-630.
27. Zanni MP, von Greyerz S, Schnyder B, Wendland T, Pichler WJ. Allele-unrestricted presentation of lidocaine by HLA-DR molecules to specific alphabeta+ T-cell clones. Int Immunol. 1998;10:507-515.
28. von Greyerz S, Bultemann G, Schnyder K, et al. Degeneracy and additional alloreactivity of drug-specific human alpha beta(+) T cell clones. Int Immunol. 2001; 13:877-885.
29. Burkhart C, Britschgi M, Strasser I, et al. Non-covalent presentation of sulfamethoxazole to human CD4+ T cells is independent of distinct human leucocyte antigen-bound peptides. Clin Exp Allergy. 2002;32:1635-1643.
30. Pirmohamed M, Park BK. Cytochrome P450 enzyme polymorphisms and adverse drug reactions. Toxicology. 2003;192:23-32.
31. Alfirevic A, Stalford AC, Vilar FJ, Wilkins EG, Park BK, Pirmohamed M. Slow acetylator phenotype and genotype in HIV-positive patients with sulphamethoxazole hypersensitivity. Br J Clin Pharmacol. 2003;55:158-165.
32. Pirmohamed M, Lin K, Chadwick D, Park BK. TNFalpha promoter region gene polymorphisms in carbamazepine-hypersensitive patients. Neurology. 2001;56:890-896.
33. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002;359:727-732.
34. Martin AM, Nolan D, Gaudieri S, et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci USA. 2004; 101:4180-4185.
35. Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 2004;428:486.
36. Hung SI, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA. 2005;102:4134-4139.
37. Christiansen C, Pichler WJ, Skotland T. Delayed allergy-like reactions to X-ray contrast media: mechanistic considerations. Eur Radiol. 2000; 10:1965-1975.
38. Christiansen C. Late-onset allergy-like reactions to X-ray contrast media. Curr Opin Allergy Clin Immunol. 2002;2:333-339.
39. Pirmohamed M, Park BK. Genetic susceptibility to adverse drug reactions. Trends Pharmacol Sci. 2001;22:298-305.
40. Vollmer J, Weltzien HU, Dormoy A, Pistoor F, Moulon C. Functional expression and analysis of a human HLA-DQ restricted, nickel-reactive T-cell receptor in mouse hybridoma, cells. J Invest Dermatol. 1999;113:175-181.
41. Pichler WJ. Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept. Curr Opin Allergy Clin Immunol. 2002;2:301-305.
42. Thierse HJ, Gamerdinger K, Junkes C, Guerreiro N, Weltzien HU. T-cell receptor (TCR) interaction with haptens: metal ions as non-classical haptens. Toxicology. 2005;209:101-107.
43. Stockl J, Majdic O, Fischer G, Maurer D, Knapp W. Monomorphic molecules function as additional recognition structures on haptenated target cells for HLA-Al -restricted, hapten-specific CTL. J Immunol. 2001;167:2724-2733.
44. Beeley N-R. Can peptides be mimicked? Drug Discov Today. 2000;5:354-363.
45. Mason D. A very high level of cross-reactivity is an essential feature of the T-cell receptor. Immunol Today. 1998; 19:395-404.
46. Pirmohamed M, Park BK. HIV and drug allergy. Curr Opin Allergy Clin Immunol. 2001; 1:311-316.
47. Engler OB, Strasser I, Naisbitt DJ, Cerny A, Pichler WJ. A chemically inert drug can stimulate T cells in vitro by their T-cell receptor in non-sensitized individuals. Toxicology. 2004;197:47-56.